Rhumbline Advisers Cullinan Oncology, Inc. Transaction History

Rhumbline Advisers

  • $113 Billion
  • Q2 2025

A detailed history of Rhumbline Advisers transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 74,105 shares of CGEM stock, worth $538,743. This represents 0.0% of its overall portfolio holdings.

Number of Shares
74,105
Previous 71,338 3.88%
Holding current value
$538,743
Previous $540,000 3.33%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 12, 2025
BUY
$7.13 - $9.08 $19,728 - $25,124
2,767 Added 3.88%
74,105 $558,000
Q1 2025

Apr 08, 2025
BUY
$7.57 - $12.68 $23,694 - $39,688
3,130 Added 4.59%
71,338 $572,000
Q4 2024

May 29, 2025
SELL
$10.77 - $17.6 $33,710 - $55,088
-3,130 Reduced 4.39%
68,208 $830,000
Q4 2024

Jan 30, 2025
BUY
$10.77 - $17.6 $57,597 - $94,124
5,348 Added 8.51%
68,208 $830,000
Q3 2024

Nov 12, 2024
BUY
$16.03 - $20.86 $136,399 - $177,497
8,509 Added 15.66%
62,860 $1.05 Million
Q2 2024

Aug 01, 2024
BUY
$15.63 - $29.35 $119,553 - $224,498
7,649 Added 16.38%
54,351 $947,000
Q1 2024

May 09, 2024
BUY
$10.17 - $19.02 $9,885 - $18,487
972 Added 2.13%
46,702 $795,000
Q4 2023

Feb 08, 2024
BUY
$7.89 - $10.23 $3,873 - $5,022
491 Added 1.09%
45,730 $465,000
Q3 2023

Nov 09, 2023
SELL
$9.05 - $11.72 $8,941 - $11,579
-988 Reduced 2.14%
45,239 $409,000
Q2 2023

Aug 08, 2023
SELL
$8.8 - $13.4 $42,820 - $65,204
-4,866 Reduced 9.52%
46,227 $497,000
Q1 2023

May 11, 2023
BUY
$10.2 - $11.91 $44,880 - $52,404
4,400 Added 9.42%
51,093 $523,000
Q4 2022

Feb 14, 2023
BUY
$9.72 - $13.62 $8,854 - $12,407
911 Added 1.99%
46,693 $493,000
Q3 2022

Nov 10, 2022
BUY
$11.82 - $15.42 $31,429 - $41,001
2,659 Added 6.17%
45,782 $587,000
Q2 2022

Aug 11, 2022
BUY
$7.31 - $13.55 $80,980 - $150,106
11,078 Added 34.57%
43,123 $553,000
Q1 2022

May 12, 2022
BUY
$10.47 - $16.75 $15,129 - $24,203
1,445 Added 4.72%
32,045 $336,000
Q4 2021

Feb 10, 2022
SELL
$15.36 - $25.0 $6,528 - $10,625
-425 Reduced 1.37%
30,600 $472,000
Q3 2021

Nov 12, 2021
BUY
$22.56 - $29.68 $360,914 - $474,820
15,998 Added 106.46%
31,025 $700,000
Q2 2021

Aug 05, 2021
BUY
$24.96 - $41.25 $85,937 - $142,023
3,443 Added 29.72%
15,027 $387,000
Q1 2021

May 06, 2021
BUY
$28.0 - $53.42 $324,352 - $618,817
11,584 New
11,584 $483,000

Others Institutions Holding CGEM

# of Institutions
152
Shares Held
68.3M
Call Options Held
15.6K
Put Options Held
17.9K
View Full List

About Cullinan Oncology, Inc.

CGEM Quotes by TradingView
  • Ticker CGEM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,612,200
  • Market Cap $332M
  • Description
  • Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...
More about CGEM
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email